Table 2.

Reduction in tumor vascular permeability after anti-VEGF/VPF treatment: LS174T tumors in dorsal skinfold chambers

Control	Antibody-treated	Time, h
2.26	1.69
(0.95–3.69)	(0.83–1.83)	6
4.78	1.20
(3.50–5.16)	(1.07–3.22)*	24
2.33	0.65
(2.05–5.87)	(0.63–0.75)*	72
2.24	0.88
(0.66–8.08)	(0.49–4.07)	120

The permeability data (10⁻⁷ cm/s) are shown as median (range). The antibody (492 μg/ml) or PBS was administered 7–23 days after tumor transplantation, depending on the growth rate and vascularization of tumors. The dose of each injection was 0.2 ml. The measurement was performed at various time points after a bolus i.v. injection of the anti-VEGF antibody (N = 3) or PBS (N = 3). 

^*P < 0.05 vs the matched control.